Pure Global AI
Japan flag

Japan medical device registration timeline

Source-linked clocks

Pharmaceuticals and Medical Devices Agency (PMDA) review clocks and end-to-end planning ranges, using the 4-class (I, II, III, IV) classification system.

6 pathways6 of 6 clocks verifiedvalidity The approval, certification or notification itself does not expire. What expires around it is the paperwork: the marketing-authorisation licence is renewed every 5 years, and the QMS conformity investigation must be repeated on a 5-year cycle. New devices additionally carry a re-examination period fixed at approvalMDSAP acceptedreviewed 2026-08-30pmda.go.jp
Class / pathwayReview clockPlanning totalWith prior approvalProvenance
Class I (一般医療機器)(Pre-marketing notification (製造販売届, Todokede) to PMDA)
PMDA states plainly that it does not review the notification (提出された届書については審査を行いません) — it is filed on the notifier’s own responsibility, so there is no decision period to wait out
0 days0 days—Verified
Third-party certification (認証)(Registered certification body (登録認証機関) under Art. 23-2-23)
Zero is recorded because the government sets no clock here, not because certification is instant: Enforcement Regulation Art. 129(3)(i) makes each registered certification body state its own standard processing period in the business rules it files for MHLW approval, so the period is per-body and there is no national figure to publish
0 days5-6 months—Verified
New medical device application (新医療機器)(PMDA approval review (Shonin))
PMDA publishes this target by application type, not by risk class; priority-review new devices have a 9-month target
12 months7.1-12 months—Verified
Improved device — clinical data (改良医療機器(臨床あり))(PMDA approval review (Shonin))
PMDA publishes this target by application type, not by risk class
9 months6.5-8.8 months—Verified
Improved device — no clinical data (改良医療機器(臨床なし))(PMDA approval review (Shonin))
PMDA publishes this target by application type, not by risk class
6 months4.9-7.3 months—Verified
Follower medical device application (後発医療機器)(PMDA approval review (Shonin))
PMDA publishes this target by application type, not by risk class
4 months2-6 months—Verified
Review clocks exclude applicant hold time · planning totals are estimates

Planning steps and estimates; these are not regulator deadlines.

Japan Medical Device Registration Process

Step-by-step PMDA registration process. Total estimated timeline: 0 days.

Step 1: Device Classification

2-4 weeks

Classify device under PMDA rules: Class I (Todokede), II-III (Ninsho), III-IV (Shonin).

Step 2: Appoint MAH/DMAH

4-8 weeks

Foreign manufacturers must appoint a Marketing Authorization Holder (MAH) in Japan.

Step 3: Foreign Manufacturer Accreditation

1-2 months

Register foreign manufacturing site with PMDA. Required before product registration.

Step 4: QMS Compliance

2-4 months

PMDA conducts QMS/GMP audit of manufacturing site. MDSAP accepted as alternative.

Step 5: Pre-Submission Consultation

1-3 months

Recommended for Class III/IV devices. Discuss clinical data and testing requirements.

Step 6: Shonin/Ninsho Application

1-2 weeks

Submit application to PMDA (Shonin) or Registered Certification Body (Ninsho).

Step 7: PMDA Review

10-14 months

Technical review by PMDA. Average 10-14 months for Shonin (Class III-IV).

Step 8: Approval

2-4 weeks

MHLW issues approval. Device can be marketed in Japan through the MAH.

Summary: The Japan medical device registration process through Pharmaceuticals and Medical Devices Agency (PMDA) consists of 8 main steps: Device Classification → Appoint MAH/DMAH → Foreign Manufacturer Accreditation → QMS Compliance → Pre-Submission Consultation → Shonin/Ninsho Application → PMDA Review → Approval.
Expedited pathways
SAKIGAKE Designation (先駆け審査指定制度)6-month total review target, against the 12-month guide for an ordinary new device

Pioneer designation for devices developed in Japan first, carrying prioritised consultation and a dedicated PMDA concierge

Eligibility: Ground-breaking technology, Severe disease with high unmet need, Early development in Japan

Priority Review (優先審査)9-month guide, or 10 months at the 80th percentile under the mid-term plan, against 12 and 14 for ordinary new devices

Expedited review for serious conditions

Eligibility: Serious condition, Limited treatment options

Prior approval recognition
FDA 510(k)STED documentation can be adapted; no abridged Japanese period2-4 months prep
EU CE MarkISO 13485 applicable to Ordinance 169; no abridged Japanese period2-4 months prep
MDSAPSingle audit satisfies PMDA QMS3-6 months
Key requirements
  • Marketing Authorization Holder (MAH) in Japan
  • Foreign Manufacturer Registration (FMR)
  • QMS certification (MHLW Ordinance 169)
  • Japanese labeling and IFU
  • JMDN classification
  • Route is decided by the JMDN general name, not by the applicant: Class I notifies, a Class II or designated Class III name with a certification standard is certified by a registered body, and everything else is approved by MHLW on a PMDA review
  • The application category (new / improved with clinical / improved without clinical / follower) is what sets both the review clock and the fee, so the same physical device can sit on very different timelines depending on how much of it is novel

MDSAP: Single audit satisfies PMDA QMS requirements

Primary regulator sources

Reviewed 2026-08-30. End-to-end totals remain planning estimates.

Keep researching this market
View the Japan resource hub →
Compare timeline across all countries →
Source-linked review clocks verified against PMDA publications · full review 2026-08-30 · row IDs are stable — cite as registration-timeline:japan:class-i